       Document 0338
 DOCN  M9440338
 TI    In vitro spontaneous production of anti-SIV antibodies is a reliable
       tool in the follow-up of protection of SIV-vaccinated monkeys.
 DT    9404
 AU    Zamarchi R; Veronese ML; Titti F; Geraci A; Verani P; Rossi GB; Amadori
       A; Chieco-Bianchi L; Institute of Oncology, University of Padova, Padua,
       Italy.
 SO    AIDS Res Hum Retroviruses. 1993 Nov;9(11):1139-44. Unique Identifier :
       AIDSLINE MED/94145749
 AB    To assess the reliability of the spontaneous in vitro synthesis of
       simian immunodeficiency virus (SIV)-specific antibodies as a marker in
       the monitoring of protection in SIV-vaccinated animals, Macaca
       fascicularis monkeys were immunized with formalin-inactivated SIVmac251
       or SIVmac251/32H, and challenged with human-derived (SIVmac251/32H) or
       monkey-derived live SIV. As judged by virus isolation and polymerase
       chain reaction (PCR) techniques, immunized animals were protected
       against human-derived SIV challenge, and no spontaneous in vitro
       synthesis of anti-SIV antibody was observed in nonstimulated peripheral
       blood mononuclear cell cultures over a 4-month follow-up. On the
       contrary, human cell-grown SIVmac251 immunization did not afford
       protection against monkey-derived SIV, and all the animals became
       infected and showed spontaneous in vitro synthesis of anti-SIV
       antibodies. These data demonstrate that lack of protection in
       SIV-vaccinated monkeys is strictly associated with PBMC ability of
       spontaneously produce anti-SIV antibodies in vitro following challenge,
       and suggest that this parameter might also constitute a reliable marker
       for monitoring protection in large-scale HIV vaccination and
       immunotherapy programs.
 DE    Animal  Antibodies, Viral/*BIOSYNTHESIS  Evaluation Studies  Female
       Human  In Vitro  Leukocytes, Mononuclear/IMMUNOLOGY  Macaca fascicularis
       Pokeweed Mitogens/PHARMACOLOGY  Simian Acquired Immunodeficiency
       Syndrome/IMMUNOLOGY/*PREVENTION  & CONTROL  Support, Non-U.S. Gov't
       SIV/*IMMUNOLOGY  Vaccines, Inactivated/PHARMACOLOGY  Viral
       Vaccines/*PHARMACOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

